Responses
Regular and young investigator award abstracts
Combination immunotherapies
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity
Compose a Response to This Article
Other responses
No responses have been published for this article.
